Related references
Note: Only part of the references are listed.Association Between Tenofovir Exposure and Reduced Kidney Function in a Cohort of HIV-Positive Patients: Results From 10 Years of Follow-up
Claudie Laprise et al.
CLINICAL INFECTIOUS DISEASES (2013)
The Uncertainty of the eGFR
Tony Badrick et al.
INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY (2013)
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care
Robert C. Kalayjian et al.
AIDS (2012)
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir
Jim Young et al.
AIDS (2012)
Association of tenofovir exposure with kidney disease risk in HIV infection
Rebecca Scherzer et al.
AIDS (2012)
High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy
Anna Bonjoch et al.
ANTIVIRAL RESEARCH (2012)
Antiretroviral Treatment of Adult HIV Infection 2012 Recommendations of the International Antiviral Society-USA Panel
Melanie A. Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation
Munehiro Yoshino et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2012)
Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients
Fowzia Ibrahim et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity
Saskia M. E. Vrouenraets et al.
AIDS (2011)
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir
Alana Brennan et al.
AIDS (2011)
Is Tenofovir-Related Renal Toxicity Incompletely Reversible?
Lucy J. Campbell et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2011)
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
Amanda Mocroft et al.
AIDS (2010)
Systematic Review and Meta-analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV-Infected Patients
Ryan D. Cooper et al.
CLINICAL INFECTIOUS DISEASES (2010)
Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men
Karen Wever et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients
Michael Horberg et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities
Leal C. Herlitz et al.
KIDNEY INTERNATIONAL (2010)
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir
Pablo Labarga et al.
AIDS (2009)
Progressive Renal Tubular Dysfunction Associated with Long-Term Use of Tenofovir DF
Ei Kinai et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2009)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study
Sonia Rodriguez-Novoa et al.
CLINICAL INFECTIOUS DISEASES (2009)
Spectrum of chronic kidney disease in HIV-infected patients
L. J. Campbell et al.
HIV MEDICINE (2009)
Tenofovir-associated renal and bone toxicity
C. L. N. Woodward et al.
HIV MEDICINE (2009)
Biological variation of cystatin C and creatinine
Mark Reinhard et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2009)
Circadian Variability of Cystatin C, Creatinine, and Glomerular Filtration Rate (GFR) in Healthy Men during Normal Sleep and after an Acute Shift of Sleep
Anders Larsson et al.
CHRONOBIOLOGY INTERNATIONAL (2008)
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy
Andrew Reid et al.
CLINICAL INFECTIOUS DISEASES (2008)
Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2)
Yuichi Uwai et al.
PHARMACEUTICAL RESEARCH (2007)
Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir
Brian P. Kearney et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Tenofovir-related nephrotoxicity: Case report and review of the literature
CW James et al.
PHARMACOTHERAPY (2004)
Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial
JE Gallant et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques
KKA Van Rompay et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks
G Biesecker et al.
ANTIVIRAL RESEARCH (2003)
Fanconi syndrome and renal failure induced by tenofovir: A first case report
D Verhelst et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2002)
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study
RT Schooley et al.
AIDS (2002)
Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors
G Birkus et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Share Paper
